Autolus Therapeutics plc

Listed Company

AUTLCIK 0001730463NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)X0GBFY ends Dec 31

Period

FY 2025

Revenue

$75.39M

Net Income

$-287.50M

Total Assets

$589.07M

Equity

$178.13M

Shares Out

266.16M

Op. Cash Flow

$-283.57M

AUTL$1.45−39.83% · past yearDBEQ Basic

Daily closing prices

Business

Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company developing and manufacturing next-generation T cell therapies for cancer and autoimmune diseases using proprietary modular programming technologies. The company's lead product is AUCATZYL (obecabtagene autoleucel), a CD19 CAR T cell therapy approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus operates a clinical-stage pipeline targeting hematological cancers, multiple myeloma, and autoimmune disorders, with manufacturing at its dedicated facility in Stevenage, U.K.

Summary from 10-K filed 2026-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue, net	75	10	—	—	—
Cost of sales	−96	−11	0	—	—
Research and development expenses, net	−118	−138	−130	−117	−111
Selling, general and administrative expenses	−132	−102	−47	—	—
Loss from operations	−271	−241	−180	−143	−141
Other income, net	515,000	220,000	222,000	2	−145,000
Foreign exchange gains (losses), net	2	−1	3	—	—
Interest income	19	32	14	2	262,000
Interest expense, net	−37	−9	−45	—	—
Total other income (expenses), net	−15	22	−29	−5	−988,000
Net loss before income tax	−286	−219	−208	−149	−142
Income tax expense	−2	−2	19,000	−300,000	−100,000
Net loss	−288	−221	−208	−149	−142
Foreign currency exchange translation adjustment	23	135,000	10	−30	−3
Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0 and $0	475,000	−317,000	0	—	—
Total other comprehensive income (loss), net of tax	24	−182,000	10	—	—
Total comprehensive loss	−264	−221	−198	−179	−145
Basic net loss per ordinary share (in usd per share)	−1.08	−0.86	−1.2	−1.57	−1.97
Diluted net loss per ordinary share (in usd per share)	−1.08	−0.86	−1.2	−1.57	−1.97
Weighted-average basic ordinary shares (in shares)	266	255	174	95	72
Weighted-average diluted ordinary shares (in shares)	266	255	174	95	72

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2023 2023-09-30	FY 2023 2023-06-30
Cash and cash equivalents	104	227	240	256	308
Marketable securities - Available-for-sale debt securities	197	361	0	—	—
Restricted cash	2	1	769,000	434,000	332,000
Accounts receivable, net	24	15,000	—	—	—
Inventories, net	33	4	0	—	—
Prepaid expenses and other current assets	76	67	35	52	48
Total current assets	436	661	275	308	355
Property and equipment, net	64	50	35	35	37
Intangible assets, net	20	12	0	—	—
Prepaid expenses and other non-current assets	249,000	170,000	380,000	136,000	295,000
Operating lease right-of-use assets, net	65	55	61	59	54
Long-term deposits	1	963,000	983,000	943,000	2
Deferred tax asset	4	3	3	3	2
Total assets	589	783	375	406	451
Accounts payable	3	2	103,000	661,000	4
Accrued expenses and other liabilities	56	52	40	31	31
Operating lease liabilities, current	5	3	5	5	6
Liabilities related to future royalties and milestones, net - current	10	4	—	—	—
Total current liabilities	73	61	45	38	41
Operating lease liabilities, non-current	67	50	48	47	45
Liabilities related to future royalties and milestones, net - non-current	270	245	—	—	—
Other long-term payables	477,000	426,000	357,000	295,000	122,000
Total liabilities	411	355	264	226	222
Commitments and contingencies	—	—	—	—	—
Additional paid-in capital	1,570	1,556	1,019	1,016	1,013
Accumulated other comprehensive loss	−5	−29	−29	−34	−28
Accumulated deficit	−1,387	−1,099	−879	−801	−756
Total shareholders' equity	178	427	111	181	229
Total liabilities and shareholders' equity	589	783	375	406	451

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation on property and equipment	8	8	7	7	8
Amortization of intangible assets	2	200,000	0	—	—
Inventory reserves and write-offs	12	0	—	—	—
Loss on disposal of property and equipment	14,000	223,000	4	515,000	672,000
Share-based compensation net of amounts capitalized	14	15	11	12	10
Interest expense accrued on liabilities related to future royalties and milestones, net	36	9	45	9	1
Accretion of available-for-sale securities	−8	−1	0	—	—
Foreign exchange differences	−3	2	−8	4	0
Non-cash operating lease expense	−6	5	4	3	4
Loss on termination of operating lease	0	176,000	95,000	0	0
Impairment of operating lease right-of-use assets and related property and equipment	300,000	400,000	—	—	—
Deferred income tax	−286,000	−185,000	−986,000	−268,000	−72,000
Increase in prepaid expenses and other current assets	−4	−34	11	−11	6
(Increase) decrease in prepaid expenses and other non-current assets	−266,000	938,000	2	161,000	503,000
Increase in inventories, net	−40	−4	0	—	—
Increase in accounts receivable, net	−24	0	—	—	—
Decrease in long-term deposits	0	5,000	937,000	−5,000	575,000
Increase in accounts payable	1	2	−509,000	22,000	−2
Increase in accrued expenses and other liabilities	1	12	998,000	16	−2
Increase (decrease) in operating lease liability	15	−369,000	−14	−5	−2
Net cash used in operating activities	−284	−206	−146	−112	−118
Acquisition of property and equipment	−19	−22	−11	−11	−9
Acquisition of intangibles assets	−8	−13	0	—	—
Purchases of marketable securities: available-for-sale debt securities	−243	−360	0	—	—
Proceeds from maturities and redemptions of marketable securities: available-for-sale debt securities	428	0	—	—	—
Net cash provided by (used in) investing activities	158	−395	−11	−11	−9
Proceeds from issuance of ordinary shares	0	550	0	164	246
Proceeds from exercise of share options	0	602,000	27,000	117,000	125,000
Proceeds from liabilities related to future royalties and milestones, net	0	70	0	70	50
Payments of equity issuance costs	0	−29	−910,000	−10	−11
Payments of issuance costs related to the liabilities related to future royalties and milestones, net	0	−2	0	0	−509,000
Payments of revenue share	−4	0	—	—	—
Net cash (used in) provided by financing activities	−4	590	−883,000	224	284
Effect of exchange rate changes on cash, cash equivalents and restricted cash	6	−261,000	15	−28	−754,000
Net decrease in cash, cash equivalents and restricted cash	−123	−12	−142	72	157
Cash paid for income taxes	2	2	−551,000	—	—
Property and equipment purchases included in accounts payable or accrued expenses	1	2	433,000	3	4
Leased assets terminated and obtained in exchange for operating lease liabilities, net	0	−975,000	3,000	0	29
Leased assets obtained in exchange for operating lease liabilities	10	2	41	10	627,000
Capitalized share-based compensation, net of forfeitures	76,000	3,000	46,000	—	—
Capitalized implementation costs included in accrued expenses	130,000	816,000	564,000	230,000	100,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Autolus Therapeutics plc's CIK number?

Autolus Therapeutics plc's SEC CIK number is 0001730463 (1730463). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Autolus Therapeutics plc's SEC filings?

All of Autolus Therapeutics plc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Autolus Therapeutics plc last report earnings?

Autolus Therapeutics plc (AUTL) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001730463-26-000058). This is Autolus Therapeutics plc's most recent earnings filing of record — not a forecast of its next earnings date.

What is Autolus Therapeutics plc's most recent earnings 8-K?

Autolus Therapeutics plc's latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001730463-26-000058. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Autolus Therapeutics plc's latest earnings 8-K →
Look up any company's CIK number →